Bristol-Myers Squibb Company (ETR:BRM)
55.33
+0.88 (1.62%)
Mar 31, 2025, 2:00 PM CET
Bristol-Myers Squibb Company Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
34,100
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€1,368,122
Profits / Employee
€253,457
Market Cap
112.45B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Merck KGaA | 59,020 |
Siemens Healthineers AG | 72,000 |
Fresenius SE & Co. KGaA | 176,486 |
Bayer Aktiengesellschaft | 90,587 |
Sartorius Aktiengesellschaft | 13,528 |
Fresenius Medical Care AG | 111,513 |
Carl Zeiss Meditec AG | 5,730 |
Fielmann Group AG | 23,412 |
Bristol-Myers Squibb Company News
- 1 day ago - Bristol-Myers Squibb (BMY) Among Cramer's Top Pharmaceutical Picks - GuruFocus
- 2 days ago - Bristol Myers Squibb gets positive CHMP opinion for neoadjuvant Opdivo and chemotherapy - Seeking Alpha
- 3 days ago - Bristol Myers Squibb gets CHMP positive opinion for Opdivo in multiple solid tumors - Seeking Alpha
- 3 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1... - Wallstreet:Online
- 3 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - Benzinga
- 3 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications - Wallstreet:Online
- 5 days ago - 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results - Benzinga
- 5 days ago - Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold - Seeking Alpha